These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34828612)

  • 21. Evaluation of Prevalence of Side-Effects Associated with Booster Dose of mRNA-Based COVID-19 Vaccine Among Healthcare Workers in Eastern Province, Saudi Arabia: A Descriptive Cross-Sectional Study.
    Ali MD; Almadan LZ; Alghamdi RA; Alghamdi AS; Almarhoon SA; Hassan YAM; Ahmad A; Ghosn SA; Banu N; Eltrafi Z
    Infect Drug Resist; 2022; 15():4335-4346. PubMed ID: 35971558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.
    Makanut S; Wangteeraprasert A; Jitpewngam W; Ngoenkam J; Pongcharoen S
    Vaccine; 2023 Jun; 41(29):4335-4340. PubMed ID: 37301707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study.
    Chiew CJ; Premikha M; Chong CY; Wei WE; Ong B; Lye DC; Heng D; Lee VJ; Tan KB
    Lancet Infect Dis; 2023 Feb; 23(2):177-182. PubMed ID: 36182678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kinetics of Neutralizing Antibodies against Omicron Variant in Vietnamese Healthcare Workers after Primary Immunization with ChAdOx1-S and Booster Immunization with BNT162b2.
    Chau NVV; Nguyet LA; Dung NT; Quang VM; Truong NT; Toan LM; Hung LM; Man DNH; Khoa DB; Phong NT; Ngoc NM; Thao HP; Ty DTB; Thanh PB; Ny NTH; Thanh LK; Thuy CT; Anh NT; Hong NTT; Nhu LNT; Yen LM; Thwaites G; Thanh TT; Tan LV;
    Am J Trop Med Hyg; 2023 Jan; 108(1):137-144. PubMed ID: 36450229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.
    Andrews N; Stowe J; Kirsebom F; Toffa S; Rickeard T; Gallagher E; Gower C; Kall M; Groves N; O'Connell AM; Simons D; Blomquist PB; Zaidi A; Nash S; Iwani Binti Abdul Aziz N; Thelwall S; Dabrera G; Myers R; Amirthalingam G; Gharbia S; Barrett JC; Elson R; Ladhani SN; Ferguson N; Zambon M; Campbell CNJ; Brown K; Hopkins S; Chand M; Ramsay M; Lopez Bernal J
    N Engl J Med; 2022 Apr; 386(16):1532-1546. PubMed ID: 35249272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SARS-CoV-2 variants and the global pandemic challenged by vaccine uptake during the emergence of the Delta variant: A national survey seeking vaccine hesitancy causes.
    AlJamaan F; Temsah MH; Alhasan K; Alenezi S; Alhaboob A; Alrabiaah A; Batais M; Alshahrani F; Assiri RA; Bafaqih H; Alaraj A; Al Qadrah B; Alhaidary A; Saad K; Saddik B; Halwani R; Rabaan AA; Al-Subaie S; Barry M; Al-Tawfiq JA
    J Infect Public Health; 2022 Jul; 15(7):773-780. PubMed ID: 35728424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents.
    Canaday DH; Oyebanji OA; White E; Keresztesy D; Payne M; Wilk D; Carias L; Aung H; St Denis K; Sheehan ML; Berry SD; Cameron CM; Cameron MJ; Wilson BM; Balazs AB; King CL; Gravenstein S
    EBioMedicine; 2022 Jun; 80():104066. PubMed ID: 35605428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
    Abu-Raddad LJ; Chemaitelly H; Ayoub HH; AlMukdad S; Yassine HM; Al-Khatib HA; Smatti MK; Tang P; Hasan MR; Coyle P; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R
    N Engl J Med; 2022 May; 386(19):1804-1816. PubMed ID: 35263534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine.
    Yavuz E; Günal Ö; Başbulut E; Şen A
    J Med Virol; 2022 Aug; 94(8):3768-3775. PubMed ID: 35434796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Turkish Healthcare Workers' Personal and Parental Attitudes to COVID-19 Vaccination From a Role Modeling Perspective.
    Öncel S; Alvur M; Çakıcı Ö
    Cureus; 2022 Feb; 14(2):e22555. PubMed ID: 35371785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acceptance of the COVID-19 vaccine booster dose and associated factors among the elderly in China based on the health belief model (HBM): A national cross-sectional study.
    Qin C; Yan W; Du M; Liu Q; Tao L; Liu M; Liu J
    Front Public Health; 2022; 10():986916. PubMed ID: 36589991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COVID-19 Vaccine Booster Hesitancy (VBH) and Its Drivers in Algeria: National Cross-Sectional Survey-Based Study.
    Lounis M; Bencherit D; Rais MA; Riad A
    Vaccines (Basel); 2022 Apr; 10(4):. PubMed ID: 35455371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Humoral Response in Hemodialysis Patients Following COVID-19 Vaccination and Breakthrough Infections during Delta and Omicron Variant Predominance.
    Chinnadurai R; Wu HHL; Cox E; Moore J; Clough T; Lamerton E; Donne R; O'Riordan E; Poulikakos D
    Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection.
    Vietri MT; D'Elia G; Caliendo G; Passariello L; Albanese L; Molinari AM; Angelillo IF
    Vaccine; 2022 Sep; 40(39):5726-5731. PubMed ID: 36041940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022.
    Prasad N; Derado G; Nanduri SA; Reses HE; Dubendris H; Wong E; Soe MM; Li Q; Dollard P; Bagchi S; Edwards J; Shang N; Budnitz D; Bell J; Verani JR; Benin A; Link-Gelles R; Jernigan J; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2022 May; 71(18):633-637. PubMed ID: 35511708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
    Tan NH; Geers D; Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Bogers S; van Dijk LLA; Gommers L; van Leeuwen LPM; Boerma A; Nijhof SH; van Dort KA; Koopmans MPG; Dalm VASH; Lafeber M; Kootstra NA; Huckriede ALW; van Baarle D; Zaeck LM; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
    Lancet Infect Dis; 2023 Aug; 23(8):901-913. PubMed ID: 37088096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP.
    Hulme WJ; Horne EMF; Parker EPK; Keogh RH; Williamson EJ; Walker V; Palmer TM; Curtis HJ; Walker AJ; Andrews CD; Mehrkar A; Morley J; MacKenna B; Bacon SCJ; Goldacre B; Hernán MA; Sterne JAC
    BMJ; 2023 Mar; 380():e072808. PubMed ID: 36921925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial.
    Corominas J; Garriga C; Prenafeta A; Moros A; Cañete M; Barreiro A; González-González L; Madrenas L; Güell I; Clotet B; Izquierdo-Useros N; Raïch-Regué D; Gallemí M; Blanco J; Pradenas E; Trinité B; Prado JG; Blanch-Lombarte O; Pérez-Caballero R; Plana M; Esteban I; Pastor-Quiñones C; Núñez-Costa X; Taleb RA; McSkimming P; Soriano A; Nava J; Anagua JO; Ramos R; Lluch RM; Comes AC; Romero SO; Gomez XM; Sans-Pola C; Moltó J; Benet S; Bailón L; Arribas JR; Borobia AM; Parada JQ; Navarro-Pérez J; Forner Giner MJ; Lucas RO; Jiménez MDMV; Compán SO; Alvarez-Mon M; Troncoso D; Arana-Arri E; Meijide S; Imaz-Ayo N; García PM; de la Villa Martínez S; Fernández SR; Prat T; Torroella È; Ferrer L
    Lancet Reg Health Eur; 2023 May; 28():100613. PubMed ID: 37131861
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.